10m agoGuruFocusBULLISH 72Earnings
Why Is REGENERON PHARMACEUT (REGN) Stock Moving Today?
By the Top Tier Newswire AI Desk · reviewed against 11 wire stories
REGENERON PHARMACEUT (REGN) is drawing unusual attention today. Our newswire has captured 11 stories on REGN across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 67/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for REGN publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
REGN by the numbers
7 sessions: +5.92%Coverage: 11 stories / 5 sourcesAI sentiment: 67/100 (bullish)
The headlines behind the move
40m agoGuruFocusBULLISH 74Earnings
Regeneron Pharmaceuticals Reports Q3 2026 EPS of $18.45 and Revenue of $5.1 Billion, Surpassing Estimates
1h agoBusiness InsiderBULLISH 74Earnings
Regeneron posts Q3 beat after 36% YoY growth driven by Sanofi tie-up
Regeneron Pharmaceuticals (REGN) stock rises as the company posts higher-than-expected Q3 2026 results thanks to its Sanofi (SNY) collaboration. Read more here.
1h agoGuruFocusBULLISH 67Earnings
Regeneron Pharmaceuticals (REGN) Reports Q3 Revenue Beat, Strengthens Pipeline
1h agoGuruFocusBULLISH 64Earnings
Regeneron Pharmaceuticals (REGN) Posts Strong Q3 Results, Maintains Modestly Undervalued Status
1h agoSEC 8-KNEUTRAL 50General
REGENERON PHARMACEUTICALS, INC. (REGN) files 8-K
Filed: 2026-10-30 AccNo: 0000872589-26-000032 Size: 681 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
1h agoThe FlyNEUTRAL 52General
Regeneron narrows FY26 CapEx view to $1.05B-$1.1B from $1.03B-$1.1B
1h agoThe FlyBULLISH 78Earnings
Regeneron reports Q3 adjusted EPS $20.07, consensus $16.25
1h agoSeeking AlphaBULLISH 78Earnings
Regeneron Pharmaceuticals Non-GAAP EPS of $20.07 beats by $3.82, revenue of $5.1B beats by $540M
Regeneron Pharmaceuticals press release (REGN): Q3 Non-GAAP EPS of $20.07 beats by $3.82. Revenue of $5.1B (+36.0% Y/Y) beats by $540M. 2026 Financial Guidance*
1h agoBusiness InsiderBULLISH 74Earnings
Regeneron Reports Third Quarter 2026 Financial and Operating Results
Third quarter 2026 revenues increased 36% to $5.1 billion versus third quarter 2025 Dupixent ® global net sales (recorded by Sanofi) increased 35% to $6.
Frequently asked questions
Why is REGN stock moving today?
REGENERON PHARMACEUT (REGN) is drawing unusual attention today. Our newswire has captured 11 stories on REGN across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 67/100). The most recent driver: "Regeneron (REGN) Shares Rise After Q3 Earnings Beat Expectations" (GuruFocus).
Is REGN a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of REGN coverage reads 67/100 over 11 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is IOVA down today (-35.45%)
- Why is GKOS up today (+33.65%)
- Why is ADT up today (+33.20%)
- Why is BHC up today (+28.76%)
- Why is PRCH up today (+28.16%)
- Why is NOW down today (-26.95%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on REGN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.